{
    "clinical_study": {
        "@rank": "131131", 
        "arm_group": [
            {
                "arm_group_label": "Nifedipine", 
                "arm_group_type": "Active Comparator", 
                "description": "Women will receive an initial dose of oral nifedipine 10mg.  If blood pressure exceeds 155mmHg systolic OR 105 mmHg diastolic after 1h, an additional 10mg dose can be provided each hour for two additional doses (30 mg total)."
            }, 
            {
                "arm_group_label": "Methyldopa", 
                "arm_group_type": "Experimental", 
                "description": "Women will receive an initial dose of oral methyldopa 1000mg. No additional escalation in dose in the first 6 hours will be given."
            }, 
            {
                "arm_group_label": "Labetalol", 
                "arm_group_type": "Experimental", 
                "description": "Women will receive an initial dose of oral labetalol 200mg.  If blood pressure exceeds 155mmHg systolic OR 105 mmHg diastolic after 1h, an additional 200mg dose can be provided each hour for two additional doses (600 mg total)."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a pragmatic, open-label, randomised control trial of three oral anti-hypertensive\n      regimens for women with severe hypertension in pregnancy. Women presenting with severe\n      hypertension in pregnancy in two hospitals in Nagpur, India will be randomised to one of\n      three oral regimens: nifedipine, labetalol or methyldopa. This trial will compare the\n      efficacy, safety and side effects of these three oral regimens for management of\n      hypertension in pregnant women. The investigators hypothesize that nifedipine treatment of\n      severe hypertensive parturient women is more effective than treatment with labetalol or\n      methyldopa in controlling high blood pressure within six hours."
        }, 
        "brief_title": "Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hypertension in Pregnancy", 
            "Preeclampsia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hypertension", 
                "Pre-Eclampsia", 
                "Hypertension, Pregnancy-Induced"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a pragmatic, open-label, randomised control trial of three oral anti-hypertensive\n      regimens for women with severe hypertension in pregnancy. Women presenting with severe\n      hypertension in pregnancy in two hospitals in Nagpur, India will be randomised to one of\n      three oral regimens: nifedipine, labetalol or methyldopa. This trial will compare the\n      efficacy, safety and side effects of these three oral regimens for management of\n      hypertension in pregnant women. The investigators hypothesize that nifedipine treatment of\n      severe hypertensive parturient women is more effective than treatment with labetalol or\n      methyldopa in controlling high blood pressure within six hours."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2022 Pregnant gestational age > 28 weeks\n\n               -  Systolic blood pressure >160 mm Hg OR a diastolic blood pressure of >110 mm Hg\n                  measured twice more than 15 minutes apart\n\n               -  Able to swallow pills\n\n               -  > 18 years\n\n        Exclusion Criteria:\n\n          -  \u2022 Indication for emergent cesarean or known fetal anomaly\n\n               -  Anti-hypertensive therapy received in the past 6 hours\n\n               -  History of eclampsia or other adverse CNS complication (e.g., stroke or PRES) in\n                  this pregnancy\n\n               -  Actively wheezing at time of enrollment or history of asthma complications\n\n               -  Known coronary artery disease or type I DM with microvascular complications"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "671", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01912677", 
            "org_study_id": "4000"
        }, 
        "intervention": [
            {
                "arm_group_label": "Nifedipine", 
                "intervention_name": "Nifedipine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Labetalol", 
                "intervention_name": "Labetalol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Methyldopa", 
                "intervention_name": "Methyldopa", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antihypertensive Agents", 
                "Labetalol", 
                "Methyldopa", 
                "Nifedipine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "hypertension in pregnancy", 
            "preeclampsia", 
            "anti-hypertension", 
            "labetalol", 
            "nifedipine", 
            "methyldopa"
        ], 
        "lastchanged_date": "January 31, 2014", 
        "location": [
            {
                "contact": {
                    "email": "srmundle@gmail.com", 
                    "last_name": "Shuchita Mundle, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Nagpur", 
                        "country": "India", 
                        "state": "Maharashtra", 
                        "zip": "440003"
                    }, 
                    "name": "Government Medical College"
                }, 
                "investigator": {
                    "last_name": "Rajeshree Patil, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "srmundle@gmail.com", 
                    "last_name": "Vaishali Khedikar, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Nagpur", 
                        "country": "India", 
                        "state": "Maharashtra", 
                        "zip": "440003"
                    }, 
                    "name": "Daga Women's Hospital"
                }, 
                "investigator": {
                    "last_name": "Vaishali Khedikar, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "3", 
        "official_title": "Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy", 
        "overall_contact": {
            "email": "hbracken@gynuity.org", 
            "last_name": "Hillary Bracken, PhD", 
            "phone": "2124481230"
        }, 
        "overall_official": {
            "affiliation": "Gynuity Health Projects", 
            "last_name": "Hillary Bracken, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "India: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Successful outcome will be considered blood pressure that reaches the target (defined as 130-150mmHg systolic and 80-100 mmHg mm Hg diastolic) at 6h without an adverse outcome.", 
            "measure": "Successful outcome", 
            "safety_issue": "Yes", 
            "time_frame": "6 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01912677"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "the number of hourly BP's in severe range", 
            "measure": "number of hourly BP's in severe range", 
            "safety_issue": "Yes", 
            "time_frame": "one hour"
        }, 
        "source": "Gynuity Health Projects", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Government Medical College, Nagpur", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Daga Women's Hospital, Nagpur", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "University of British Columbia", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Gynuity Health Projects", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}